Jean‐claude Reubi

Jean‐claude Reubi's AcademicInfluence.com Rankings

Jean‐claude Reubi

Philosophy

#3601

World Rank

#5790

Historical Rank

Logic

#1267

World Rank

#1972

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Jean‐claude Reubi Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jean‐claude Reubi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients (1993) (1120)
Peptide receptors as molecular targets for cancer diagnosis and therapy. (2003) (1053)
Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use (2000) (975)
The role of somatostatin and its analogs in the diagnosis and treatment of tumors. (1991) (843)
The VPAC2 Receptor Is Essential for Circadian Function in the Mouse Suprachiasmatic Nuclei (2002) (537)
Somatostatin-receptor imaging in the localization of endocrine tumors. (1990) (529)
Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting (2003) (515)
Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. (1999) (490)
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors (2006) (431)
Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands (2001) (428)
Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. (1992) (420)
Somatostatin receptors. (1985) (415)
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting (2007) (395)
Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. (1990) (390)
Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. (1997) (331)
Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours (2004) (323)
DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals (2003) (284)
Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. (1994) (282)
A new and sensitive staining method for axonally transported horseradish peroxidase (HRP) in the pigeon visual system (1977) (279)
Somatostatin receptors in human endocrine tumors. (1987) (269)
Bombesin Receptor Subtypes in Human Cancers: Detection with the Universal Radioligand 125I-[d-TYR6, β-ALA11, PHE13, NLE14] Bombesin(6–14) (2002) (268)
Peptide-Based Probes for Cancer Imaging (2008) (264)
Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. (2000) (250)
Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting (2008) (245)
Erratum to: Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands (2001) (243)
Glucagon-like peptide-1 receptor imaging for localization of insulinomas. (2009) (236)
Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. (1999) (231)
Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. (1989) (230)
Distribution of somatostatin receptors in normal and tumor tissue. (1990) (226)
Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implications (1992) (224)
The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. (1989) (222)
PET of Somatostatin Receptor–Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference (2011) (216)
Dopamine selectively increases 3H-GABA release from slices of rat substantia nigra in vitro (1977) (214)
Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. (1995) (210)
Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. (1991) (208)
NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. (2002) (203)
Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. (1987) (201)
Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. (1990) (197)
Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study (2014) (191)
Substance‐P receptors in human primary neoplasms: Tumoral and vascular localization (1995) (191)
Autoradiographic mapping of somatostatin receptors in the rat central nervous system and pituitary (1985) (191)
Synthesis and Evaluation of Bombesin Derivatives on the Basis of Pan-Bombesin Peptides Labeled with Indium-111, Lutetium-177, and Yttrium-90 for Targeting Bombesin Receptor-Expressing Tumors (2004) (188)
Candidates for peptide receptor radiotherapy today and in the future. (2005) (184)
[99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging (2003) (183)
Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals. (1990) (183)
Glucagon-like peptide 1-receptor scans to localize occult insulinomas. (2008) (182)
Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. (2001) (181)
Glutamate release in vitro from corticostriatal terminals (1979) (181)
Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. (2010) (181)
In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. (1991) (179)
Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. (2006) (178)
Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors (2013) (177)
High incidence of somatostatin receptors in human meningiomas: biochemical characterization. (1986) (176)
High affinity binding sites for a somatostatin-28 analog in rat brain. (1981) (174)
68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5 (2005) (174)
Evidence for two somatostatin-14 receptor types in rat brain cortex (1984) (173)
Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). (2002) (169)
Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma (1998) (168)
[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. (2006) (167)
177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. (2006) (166)
Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial (2010) (164)
Somatostatin and the immune and haematopoetic system; a review (1994) (164)
First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible (2011) (163)
High density of somatostatin receptors in pituitary tumors from acromegalic patients. (1984) (161)
PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide (2002) (161)
Glutamine as precursor for the GABA and glutamate trasmitter pools (1978) (161)
Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin. (1986) (157)
Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours (2010) (157)
Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. (2005) (155)
Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. (2002) (154)
Evaluation of a 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid–Conjugated Bombesin-Based Radioantagonist for the Labeling with Single-Photon Emission Computed Tomography, Positron Emission Tomography, and Therapeutic Radionuclides (2009) (153)
In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. (1995) (149)
Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. (1987) (148)
New specific radioligand for one subpopulation of brain somatostatin receptors. (1985) (146)
Distribution of somatostatin receptors in the human brain: An autoradiographic study (1986) (146)
Somatostatin‐receptor Scintigraphy in Gastroenteropancreatic Tumors (1994) (143)
Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. (2013) (141)
Somatostatin and Other Peptide Receptors as Tools for Tumor Diagnosis and Treatment (2004) (139)
In vivo somatostatin receptor imaging in medullary thyroid carcinoma. (1993) (137)
Glucagon-Like Peptide-1 Versus Somatostatin Receptor Targeting Reveals 2 Distinct Forms of Malignant Insulinomas (2011) (137)
Immunohistochemical localization of somatostatin receptors sst2A in human tumors. (1998) (136)
Somatostatin-receptor scintigraphy in primary breast cancer (1994) (132)
Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. (1991) (131)
Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men (2014) (130)
Somatostatin receptor subtypes sst1, sst2, sst3 and sst5expression in human pituitary, gastroentero‐pancreatic and mammary tumors (1997) (126)
Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. (1996) (126)
High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor‐host interaction? (1994) (126)
DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours (2007) (126)
Multiple actions of somatostatin in neoplastic disease. (1995) (125)
Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting (2002) (125)
Somatostatin receptors in human prostate and prostate cancer. (1995) (123)
High expression of peptide receptors as a novel target in gastrointestinal stromal tumours (2004) (123)
Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P (2006) (122)
Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. (1989) (122)
Unexpected high incidence of cholecystokinin‐B/gastrin receptors in human medullary thyroid carcinomas (1996) (121)
Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses. (1987) (121)
In Vitro Evaluation of VIP/PACAP Receptors in Healthy and Diseased Human Tissues: Clinical Implications (2000) (120)
In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. (1993) (118)
Regulatory peptide receptors in human hepatocellular carcinomas (1999) (118)
Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications (2012) (117)
in vitro and in vivo detection of somatostatin receptors in human malignant lymphomas (1992) (117)
Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. (1997) (116)
Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide Treatment (2011) (115)
Expression of Somatostatin Receptors in Normal, Inflamed, and Neoplastic Human Gastrointestinal Tissues (1994) (114)
Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. (1994) (113)
Somatostatin Receptor Subtype 2A Immunohistochemistry Using a New Monoclonal Antibody Selects Tumors Suitable for In Vivo Somatostatin Receptor Targeting (2012) (112)
Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. (1996) (111)
Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. (1992) (110)
A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth. (1985) (109)
Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. (1992) (108)
In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man. (1991) (108)
Somatostatin analogue scintigraphy in granulomatous diseases (1994) (108)
Neurokinin-1 Receptor Expression and Its Potential Effects on Tumor Growth in Human Pancreatic Cancer (2003) (105)
Highly Efficient In Vivo Agonist-Induced Internalization of sst2 Receptors in Somatostatin Target Tissues (2009) (105)
Bombesin Antagonist–Based Radioligands for Translational Nuclear Imaging of Gastrin-Releasing Peptide Receptor–Positive Tumors (2011) (104)
Localization of receptors for vasoactive intestinal peptide, somatostatin, and substance P in distinct compartments of human lymphoid organs. (1998) (104)
Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). (2011) (103)
In vitro detection of somatostatin receptors in human tumors. (1992) (103)
In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. (1992) (103)
Evaluation of 177Lu-DOTA-sst2 Antagonist Versus 177Lu-DOTA-sst2 Agonist Binding in Human Cancers In Vitro (2011) (103)
NPY receptors in human cancer: A review of current knowledge (2007) (101)
Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. (1996) (100)
Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. (2005) (100)
Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. (2008) (100)
Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. (1988) (99)
Targeting GRPR in urological cancers—from basic research to clinical application (2013) (98)
First 18F-Labeled Tracer Suitable for Routine Clinical Imaging of sst Receptor-Expressing Tumors Using Positron Emission Tomography (2004) (96)
Receptor Signaling and Endocytosis Are Differentially Regulated by Somatostatin Analogs (2005) (96)
Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates. (2002) (95)
Localization of Hidden Insulinomas with 68Ga-DOTA-Exendin-4 PET/CT: A Pilot Study (2015) (95)
[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor–Targeted Therapy for Insulinoma (2007) (95)
Distribution of the VPAC2 receptor in peripheral tissues of the mouse. (2004) (94)
Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. (1997) (93)
Somatostatin receptor imaging. The presence of somatostatin receptors in rheumatoid arthritis. (1994) (93)
Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. (2003) (92)
Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease. (1994) (92)
Metastatic carcinoid tumors and the malignant carcinoid syndrome. (1993) (90)
Comparative biodistribution of 12 111In-labelled gastrin/CCK2 receptor-targeting peptides (2011) (89)
Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. (1996) (89)
Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. (2000) (88)
SST3-selective potent peptidic somatostatin receptor antagonists. (2000) (87)
Localization and characterization of neuropeptide receptors in human colon (2001) (86)
Neurotensin receptors in human neoplasms: High incidence in Ewing's sarcomas (1999) (86)
Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. (1999) (86)
[111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity? (1994) (86)
Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. (1997) (85)
A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. (2002) (85)
Illuminating somatostatin analog action at neuroendocrine tumor receptors. (2013) (84)
Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study (2002) (84)
Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer (2003) (84)
Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. (2005) (83)
Bombesin Receptors in Distinct Tissue Compartments of Human Pancreatic Diseases (2000) (82)
Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. (2010) (81)
Conformationally homogeneous heterocyclic pseudotetrapeptides as three-dimensional scaffolds for rational drug design: receptor-selective somatostatin analogues. (2009) (80)
Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. (2004) (79)
Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro‐intestinal adenocarcinoma samples: Where are they really located? (1999) (78)
Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours (2008) (78)
Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma (2000) (77)
Distribution pattern of 68Ga-DOTATATE in disease-free patients (2010) (76)
Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. (1993) (76)
Specific high affinity binding sites for somatostatin-28 on pancreatic beta-cells: differences with brain somatostatin receptors. (1982) (76)
Biodistribution and catabolism of (18)F-labeled neurotensin(8-13) analogs. (2002) (75)
Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo (1998) (75)
Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. (1999) (74)
Expression of somatostatin receptors in childhood neuroblastoma. (1994) (72)
Influence of different spacers on the biological profile of a DOTA-somatostatin analogue. (2007) (72)
Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs. (2003) (72)
Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer. (1991) (71)
Distinct topographical localisation of two somatostatin receptor subpopulations in the human cortex (1987) (70)
Distribution of CCK1 and CCK2 receptors in normal and diseased human pancreatic tissue. (2003) (70)
Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas (2015) (70)
One-step ¹⁸F-labeling of carbohydrate-conjugated octreotate-derivatives containing a silicon-fluoride-acceptor (SiFA): in vitro and in vivo evaluation as tumor imaging agents for positron emission tomography (PET). (2010) (70)
Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth. (1992) (69)
Comparative study of the release of glutamate and GABA, newly synthesized from glutamine, in various regions of the central nervous system (1980) (69)
Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease. (2000) (69)
Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. (1993) (69)
Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. (2010) (69)
Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours (2007) (68)
Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. (1997) (68)
Selective bidirectional transport of [3H]d-aspartate in the pigeon retino-tectal pathway (1981) (67)
New Pansomatostatin Ligands and Their Chelated Versions: Affinity Profile, Agonist Activity, Internalization, and Tumor Targeting (2008) (67)
Incretin Receptors in Non-Neoplastic and Neoplastic Thyroid C Cells in Rodents and Humans: Relevance for Incretin-Based Diabetes Therapy (2011) (67)
Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607 (2011) (66)
A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome. (1994) (66)
Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting. (2008) (65)
Targeted Radiotherapy of Prostate Cancer with a Gastrin-Releasing Peptide Receptor Antagonist Is Effective as Monotherapy and in Combination with Rapamycin (2013) (65)
Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. (1994) (65)
Peptide receptor expression in GEP-NET (2007) (63)
Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome. (1994) (63)
Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. (1995) (63)
The value of octreotide scintigraphy in patients with lung cancer (1994) (63)
Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets. (1998) (63)
Immunohistochemical detection of somatostatin sst2a receptors in the lymphatic, smooth muscular, and peripheral nervous systems of the human gastrointestinal tract: facts and artifacts. (1999) (63)
Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), Insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer (1990) (63)
The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. (1992) (61)
Dissociation of antiproliferative and antihormonal effects of the somatostatin analog octreotide on 7315b pituitary tumor cells. (1992) (61)
Gigantism due to pituitary mammosomatotroph hyperplasia. (1990) (61)
Value of Immunohistochemistry for Somatostatin Receptor Subtype sst2A in Cancer Tissues: Lessons From the Comparison of Anti-sst2A Antibodies With Somatostatin Receptor Autoradiography (2005) (61)
GPR87 Is an Overexpressed G-Protein Coupled Receptor in Squamous Cell Carcinoma of the Lung (2007) (61)
Somatostatin receptors in human renal cell carcinomas. (1992) (61)
64Cu- and 68Ga-labelled [Nle(14),Lys(40)(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell imaging in rats. (2014) (60)
The relationship between somatostatin, epidermal growth factor, and steroid hormone receptors in breast cancer (1989) (60)
High Expression of Somatostatin Receptor Subtype 2 (sst2) in Medulloblastoma: Implications for Diagnosis and Therapy (1999) (60)
111In-octreotide scintigraphy in oncology. (1992) (59)
In vitro detection of somatostatin receptors in human tumors. (1992) (59)
Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. (2006) (58)
In vitro and in vivo detection of somatostatin receptors in human malignant tissues. (1991) (58)
Expression of CRF1 and CRF2 receptors in human cancers. (2003) (58)
Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607 (2011) (58)
High affinity binding sites for somatostatin to rat pituitary. (1982) (58)
Glucagon-like peptide-1 (GLP-1) receptors are not overexpressed in pancreatic islets from patients with severe hyperinsulinaemic hypoglycaemia following gastric bypass (2010) (56)
Targeting CCK receptors in human cancers. (2007) (55)
111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy (2005) (55)
Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study (2017) (54)
Early over‐expression of GRP receptors in prostatic carcinogenesis (2014) (54)
Studies on the mechanism of action of the inhibitory effect of the somatostatin analog SMS 201-995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315a. (1986) (54)
Neuropeptide Y receptor expression in human primary ovarian neoplasms (2004) (54)
Different ionic requirements for somatostatin receptor subpopulations in the brain (1986) (54)
Release of exogenous glycine in the pigeon optic tectum during stimulation of a midbrain nucleus (1976) (53)
Somatostatin receptors in the adrenal (1986) (53)
High Expression of Neuropeptide Y Receptors in Tumors of the Human Adrenal Gland and Extra-Adrenal Paraganglia (2004) (52)
Highly Increased 125I-JR11 Antagonist Binding In Vitro Reveals Novel Indications for sst2 Targeting in Human Cancers (2017) (51)
Somatostatin receptor scintigraphy in non-medullary thyroid cancer. (1996) (50)
The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. (1996) (50)
Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications (2012) (49)
Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours (2000) (49)
High Expression of Neuropeptide Y1 Receptors in Ewing Sarcoma Tumors (2008) (49)
Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics (2001) (49)
Cholecystokinin-B/gastrin receptors enhance wound healing in the rat gastric mucosa. (2000) (49)
Role of the different isoforms of cyclooxygenase and nitric oxide synthase during gastric ulcer healing in cyclooxygenase-1 and -2 knockout mice. (2006) (49)
Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy. (2005) (48)
Visualization of LHRH receptors in the rat brain. (1984) (47)
Octreotide and Related Somatostatin Analogs in the Diagnosis and Treatment of Pituitary Disease and Somatostatin Receptor Scintigraphy (1993) (47)
Carcinoid of the pancreas: clinical characteristics and morphological features. (1996) (47)
Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. (2003) (47)
Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer 177Lu-AMBA (2006) (46)
N-Terminal Modifications Improve the Receptor Affinity and Pharmacokinetics of Radiolabeled Peptidic Gastrin-Releasing Peptide Receptor Antagonists: Examples of 68Ga- and 64Cu-Labeled Peptides for PET Imaging (2014) (45)
Pharmacological identity between somatostatin SS-2 binding sites and SSTR-1 receptors. (1995) (45)
Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc. (2006) (44)
Novel sst5-selective somatostatin dicarba-analogues: synthesis and conformation-affinity relationships. (2008) (44)
Evolution of Bombesin Conjugates for Targeted PET Imaging of Tumors (2012) (43)
Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy (2012) (43)
Identification of somatostatin receptors in human small cell lung carcinoma (1990) (43)
Gastrin-releasing peptide receptors in normal and neoplastic human uterus: involvement of multiple tissue compartments. (2005) (42)
Brain somatostatin receptor subpopulation visualized by autoradiography (1985) (42)
Release and distribution of endogenous 5-HT in rat substantia nigra (1978) (42)
Local up-regulation of neuropeptide receptors in host blood vessels around human colorectal cancers. (1996) (42)
Somatostatin analogs in the treatment of acromegaly. (1992) (42)
Identification of somatostatin and gastrin receptors on enterochromaffin-like cells from Mastomys gastric tumors. (1992) (42)
Specific luteinizing-hormone-releasing hormone receptor binding sites in hippocampus and pituitary: an autoradiographical study (1987) (42)
Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor. (2011) (41)
Radiolabeled Bicyclic Somatostatin-Based Analogs: A Novel Class of Potential Radiotracers for SPECT/PET of Neuroendocrine Tumors (2010) (41)
111In-octreotide scintigraphy in oncology. (1993) (41)
Visualization of the thymus by substance P receptor scintigraphy in man (1996) (41)
A possible role for somatostatin receptor scintigraphy in the diagnosis and follow-up of children with medulloblastoma (1998) (40)
Nonketotic hyperglycinemia treated with strychnine, a glycine receptor antagonist. (1978) (40)
Secretin receptors in the human liver: expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma. (2006) (40)
Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer. (2015) (40)
Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors. (2012) (40)
Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma (2014) (39)
Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogues by variation of peptide net charge and carbohydration chemistry. (2005) (39)
Design, synthesis, and biological evaluation of somatostatin-based radiopeptides. (2006) (39)
Somatostatin and the concept of peptide receptor scintigraphy in oncology. (1994) (38)
Overexpression of Gastrin-Releasing Peptide Receptors in Tumor-Associated Blood Vessels of Human Ovarian Neoplasms (2007) (38)
Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas (2005) (38)
Evaluation of somatostatin analogues for the detection and treatment of gastrinoma in a dog. (1997) (38)
Differential effects of somatostatin on adenylate cyclase as functional correlate for different brain somatostatin receptor subpopulations (1989) (38)
Neuropeptide Y Receptors in Primary Human Brain Tumors: Overexpression in High-Grade Tumors (2008) (38)
Asparagine as Precursor for Transmitter Aspartate in Corticostriatal Fibres (1980) (37)
The clinical use of somatostatin analogues in the treatment of cancer. (1990) (37)
The intestinal immune system and its relation to disease. (1993) (36)
Development of resistance to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours. (1988) (36)
Neurotensin receptors in pancreatic ductal carcinomas (2015) (36)
Preoperative localization of adult nesidioblastosis using 68Ga-DOTA-exendin-4-PET/CT (2015) (35)
Somatostatin (SRIH) messenger ribonucleic acid expression in human neuroendocrine and brain tumors using in situ hybridization histochemistry: comparison with SRIH receptor content. (1993) (34)
Clinical applications of somatostatin analogs (1990) (34)
Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues. (2009) (34)
Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake (1998) (34)
First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. (2004) (34)
Validation of somatostatin receptor scintigraphy in the localization of neuroendocrine tumors. (1993) (34)
Secretin receptors in normal and diseased human pancreas: marked reduction of receptor binding in ductal neoplasia. (2005) (33)
Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1). (2001) (33)
Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. (2010) (33)
VIP analogues inhibit small cell lung cancer growth (1992) (33)
CCK2 receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours (2009) (32)
Cellular detection of sst2A receptors in human gastrointestinal tissue (2004) (32)
PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonists. (2014) (32)
Somatostatin receptors in normal and tumoral tissue. (1988) (32)
Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP/vasoactive intestinal polypeptide receptor expression in human pituitary adenomas. (1998) (32)
Relevance of somatostatin receptors and other peptide receptors in pathology (1997) (31)
AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients (2019) (30)
Approaches to Multireceptor Targeting: Hybrid Radioligands, Radioligand Cocktails, and Sequential Radioligand Applications (2017) (30)
Distribution and coregulation of three peptide receptors in adrenals. (1986) (30)
Diurnal variation in the release of alpha-MSH from rat hypothalamus and pituitary. (1981) (30)
Vasoactive intestinal peptide (VIP) and VIP receptors: Gene expression and growth modulation in medulloblastoma and other central primitive neuroectodermal tumors of childhood (1999) (29)
Somatostatin receptor imaging in vivo by planar scintigraphy facilitates the diagnosis of canine insulinomas. (2005) (29)
High gastrin and cholecystokinin (CCK) gene expression in human neuronal, renal, and myogenic stem cell tumors: comparison with CCK-A and CCK-B receptor contents. (1999) (29)
The Glucose-Dependent Insulinotropic Polypeptide Receptor: A Novel Target for Neuroendocrine Tumor Imaging—First Preclinical Studies (2014) (29)
Tetraamine-derived bifunctional chelators for technetium-99m labelling: synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumours. (2010) (29)
A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors. (1998) (29)
Somatostatin and Thyrotrophin‐Releasing Hormone Response and Receptor Status of a Thyrotrophin‐Secreting Pituitary Adenoma: Clinical and in vitro Studies (1989) (28)
Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors. (2009) (28)
Immunocytochemistry of pituitary tumors. (1987) (28)
Three‐year recurrence‐free survival in a patient with recurrent medulloblastoma after resection, high‐dose chemotherapy, and intrathecal Yttrium‐90‐labeled DOTA0‐D‐Phe1‐Tyr3‐octreotide radiopeptide brachytherapy (2005) (28)
Treatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogs. (1990) (28)
N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo. (2005) (27)
Radiolabelled GLP-1 receptor antagonist binds to GLP-1 receptor-expressing human tissues (2014) (27)
Ring size of somatostatin analogues (ODT-8) modulates receptor selectivity and binding affinity. (2008) (27)
Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide. (1994) (27)
Glutamatergic pathways in the pigeon and the rat brain. (1981) (26)
Preclinical Evaluation of Radiolabeled DOTA-Derivatized Cyclic Minigastrin Analogs for Targeting Cholecystokinin Receptor Expressing Malignancies (2012) (26)
Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog (2010) (26)
closo-borane conjugated regulatory peptides retain high biological affinity: synthesis of closo-borane conjugated Tyr(3)-octreotate derivatives for BNCT. (2008) (26)
Somatostatin receptor 1 selective analogues: 4. Three-dimensional consensus structure by NMR. (2005) (26)
Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy. (2007) (26)
Novel Positron Emission Tomography/Computed Tomography of Diffuse Parenchymal Lung Disease Combining a Labeled Somatostatin Receptor Analogue and 2-Deoxy-2 [18F] Fluoro-D-Glucose (2012) (26)
In vivo phosphorylation of the somatostatin 2A receptor in human tumors. (2003) (25)
PET/CT Imaging of Unstable Carotid Plaque with 68Ga-Labeled Somatostatin Receptor Ligand (2017) (25)
Somatostatin receptor imaging of endocrine gastrointestinal tumors. (1992) (25)
[99mTc]Demotate 2 in the detection of sst2-positive tumours: a preclinical comparison with [111In]DOTA-tate (2006) (25)
68Ga-exendin-4 PET/CT detects insulinomas in patients with endogenous hyperinsulinemic hypoglycemia in MEN-1. (2019) (25)
[111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study (2012) (24)
In Vitro Identification of VIP Receptors in Human Tumors: Potential Clinical Implications (1996) (24)
Procholecystokinin as Marker of Human Ewing Sarcomas (2004) (24)
Gastrin in gastrointestinal diseases. (2011) (24)
Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model. (2010) (23)
Evaluation of three different families of bombesin receptor radioantagonists for targeted imaging and therapy of gastrin releasing peptide receptor (GRP-R) positive tumors. (2015) (23)
On the Terminal Homologation of Physiologically Active Peptides as a Means of Increasing Stability in Human Serum – Neurotensin, Opiorphin, B27‐KK10 Epitope, NPY (2011) (23)
Triple-Peptide Receptor Targeting In Vitro Allows Detection of All Tested Gut and Bronchial NETs (2015) (23)
Somatostatin receptor‐positive primary breast tumors: Genetic, patient and tumor characteristics (1993) (22)
Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling. (2003) (22)
Concomitant vascular GRP-receptor and VEGF-receptor expression in human tumors: Molecular basis for dual targeting of tumoral vasculature (2011) (22)
New sst4/5-selective somatostatin peptidomimetics based on a constrained tryptophan scaffold. (2007) (22)
Old and new peptide receptor targets in cancer: future directions. (2013) (22)
Ring size in octreotide amide modulates differently agonist versus antagonist binding affinity and selectivity. (2008) (22)
Molecular imaging of bombesin receptors in various tumors by Ga-68 AMBA PET/CT: First results (2007) (21)
Analgesic activity of a non-peptide imidazolidinedione somatostatin agonist: In vitro and in vivo studies in rat (2006) (21)
Somatostatin receptors in rat hippocampus: Localization to intrinsic neurons (1986) (20)
Study of a Primary Gastrinoma in the Common Hepatic Duct – A Case Report (1999) (20)
Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients. (2012) (20)
Stereochemistry of amino acid spacers determines the pharmacokinetics of (111)In-DOTA-minigastrin analogues for targeting the CCK2/gastrin receptor. (2015) (20)
Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers (2016) (20)
Syntheses, Receptor Bindings, in vitro and in vivo Stabilities and Biodistributions of DOTA‐Neurotensin(8–13) Derivatives Containing β‐Amino Acid Residues – A Lesson about the Importance of Animal Experiments (2013) (20)
Progesterone, oestradiol, somatostatin and epidermal growth factor receptors on human meningiomas and their CT characteristics. (1991) (19)
Somatostatin binding sites in human leptomeninx (1986) (19)
Pituitary somatostatin receptors: dissociation at the pituitary level of receptor affinity and biological activity for selective somatostatin analogs (1982) (19)
Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan. (2003) (19)
Characterization of a novel five-transmembrane domain cholecystokinin-2 receptor splice variant identified in human tumors (2012) (19)
Somatostatin receptors in nasopharyngeal carcinoma (2002) (19)
Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment (2007) (19)
Somatostatin receptors in differentiated ovarian tumors. (1991) (18)
Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8. (2003) (18)
Central nervous system-mediated growth inhibition of a rat prostate carcinoma by an opioid. (1985) (17)
Highly potent 4-amino-indolo[2,3-c]azepin-3-one-containing somatostatin mimetics with a range of sst receptor selectivities. (2009) (17)
Specific binding of cholecystokinin, estradiol and somatostatin to human pancreatic cancer xenografts (1991) (17)
High expression of gastrin-releasing peptide receptors in the vascular bed of urinary tract cancers: promising candidates for vascular targeting applications. (2009) (17)
Somatostatin Receptor 1 Selective Analogues: 2. Nα-Methylated Scan† (2005) (17)
Glucagonlike peptide-1 receptor: an example of translational research in insulinomas: a review. (2010) (17)
Does Somatostatin or Gastric Inhibitory Peptide Receptor Expression Correlate with Tumor Grade and Stage in Gut Neuroendocrine Tumors? (2015) (17)
N-Methylated sst2 Selective Somatostatin Cyclic Peptide Analogue as a Potent Candidate for Treating Neurogenic Inflammation. (2011) (17)
Nonpeptide somatostatin receptor agonists specifically target ocular neovascularization via the somatostatin type 2 receptor. (2008) (17)
Neuropeptide Y modulates steroid production of human adrenal H295R cells through Y1 receptors (2010) (16)
CCK receptors in human neuroendocrine tumors: Clinical implications (2001) (16)
Effects of GABA, dopamine, and substance P on the release of newly synthesized 3H-5-hydroxytryptamine from rat substantia nigra in vitro (1978) (16)
The role of peptides and their receptors as tumor markers. (1993) (16)
GLP-2 receptors in human disease: High expression in gastrointestinal stromal tumors and Crohn’s disease (2012) (16)
New Gastrin Releasing Peptide Receptor-Directed [99mTc]Demobesin 1 Mimics: Synthesis and Comparative Evaluation. (2018) (15)
Successful diffusible brachytherapy (dBT) of a progressive low-grade astrocytoma using the locally injected peptidic vector and somatostatin analogue [90Y]-DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC). (2001) (15)
[111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors. (2014) (15)
Secretin receptor promotes the proliferation of endocrine tumor cells via the PI3K/AKT pathway. (2012) (15)
Mass fragmentographic determination of endogenous glycine and glutamic acid released in vivo from the pigeon optic tectum. Effect of electric stimulation of a midbrain nucleus (1981) (15)
Somatostatin receptors in the gastrointestinal tract in health and disease. (1992) (14)
Novel sst(4)-selective somatostatin (SRIF) agonists. 4. Three-dimensional consensus structure by NMR. (2003) (14)
Slaging of Sézary syndrome with somatostatin receptor scintigraphy (1996) (13)
Increased Uptake of 111 In-Octreotide in Idiopathic Pulmonary Fibrosis (2006) (13)
Approaches to improve metabolic stability of a statine-based GRP receptor antagonist. (2017) (13)
Lack of evidence for autocrine feedback regulation by somatostatin in somatostatin receptor-containing meningiomas. (1990) (13)
Neuropeptide Y acts within the rat testis to inhibit testosterone secretion (2011) (13)
The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist (2018) (13)
Receptor imaging of human diseases using radiolabeled peptides. (1995) (13)
Clinical relevance of somatostatin receptor imaging. (1994) (13)
Kainic acid toxicity and binding in the optic tectum. (1979) (13)
[(99m)Tc]Demomedin C, a radioligand based on human gastrin releasing peptide(18-27): synthesis and preclinical evaluation in gastrin releasing peptide receptor-expressing models. (2012) (12)
A novel secretin receptor splice variant potentially useful for early diagnosis of pancreatic carcinoma. (2007) (12)
Transmitter-specific retrograde tracing of pathways? (1979) (12)
Use of isotope-labeled somatostatin analogs for visualization of islet cell tumors (1993) (12)
Wild-type and splice-variant secretin receptors in lung cancer: overexpression in carcinoid tumors and peritumoral lung tissue (2008) (12)
Erratum to: 64Cu- and 68Ga-Labelled [Nle14,Lys40(Ahx-NODAGA)NH2]-Exendin-4 for Pancreatic Beta Cell Imaging in Rats (2013) (12)
CRF receptors in the rodent and human cardiovascular systems: Species differences (2006) (12)
Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. (2005) (12)
In vivo mitogenic effects of estradiol on colon cancers: Role of gastrin and gastrin receptors (1993) (12)
Octreotide and Nonendocrine Tumors: Basic Knowledge and Therapeutic Potential (1996) (12)
Value of the radiolabelled GLP-1 receptor antagonist exendin(9–39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans (2011) (12)
First clinical evaluation of somatostatin receptor antagonist imaging (2010) (11)
March 2006 (2006) (11)
Three-dimensional consensus structure of sst2-selective somatostatin (SRIF) antagonists by NMR. (2008) (11)
Octreotide and octreotate derivatives radiolabeled with yttrium: pharmacokinetics in rats. (2002) (11)
Biochemical Neuroanatomy of the Pigeon Optic Tectum (1976) (11)
Expression of functional neurokinin-1 receptors in regenerative glands during gastric wound healing in rodents. (2004) (11)
Erratum: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors (Neuroendocrinology (2004) 80 (394-424)) (2005) (11)
N-imidazolebenzyl-histidine substitution in somatostatin and in its octapeptide analogue modulates receptor selectivity and function. (2011) (10)
Strict rules are needed for validation of G-protein-coupled receptor immunohistochemical studies in human tissues (2014) (10)
Evaluation of somatostatin biosynthesis, somatostatin receptors and tumor growth in murine medullary thyroid carcinoma. (1994) (10)
A case of antibody formation against octreotide visualized with 111In‐octreotide scintigraphy (1993) (10)
Carcinoid of the pancreas. (1997) (10)
[DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting. (2014) (10)
Novel dimeric DOTA-coupled peptidic Y1-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers (2011) (10)
Somatostatin receptors as markers for endocrine tumors. (1987) (10)
Somatostatin receptor imaging with 123I-Tyr3-Octreotide. (1990) (9)
VASOACTIVE INTESTINAL PEPTIDE PRODUCING TUMOUR CONTAINS HIGH DENSITY OF SOMATOSTATIN RECEPTORS (1987) (9)
Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging (2020) (9)
Locoregional Regulatory Peptide Receptor Targeting with the Diffusible Somatostatin Analogue 90 Y-Labeled (1999) (9)
DOTA‐NOC, A high affinity ligand of the somatostatin receptor subtypes 2, 3 and 5 for radiotherapy (2001) (9)
Persistent lack of somatostatin receptors in gastric mucosa of healing ulcers in rats. (1994) (9)
HORMONE DEPENDENCY OF MENINGIOMAS (1989) (8)
The role of somatostatin analogs in the control of tumor growth. (1994) (8)
Octreotide: an active agent in epithelial ovarian carcinoma? (2004) (8)
PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors (2013) (8)
[(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate. (2006) (8)
Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model ( 213 Bi-DOTA-PESIN and (2011) (7)
Somatostatin and Alzheimer's disease: a hypothesis (1986) (7)
Chemical Structure, Pharmacodynamic Profile and Pharmacokinetics of SMS 201–995 (Sandostatin ® ) (1988) (7)
Pharmacological identity between somatostatin SS-1 SS-2 sites and SSTR-2 (1994) (6)
Biodistribution of two octreotate analogs radiolabeled with indium and yttrium in rats. (2010) (6)
A Critical Evaluation of sst3 and sst5 Immunohistochemistry in Human Pituitary Adenomas (2017) (6)
Localization of 99mTc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses (2019) (6)
Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. (2005) (5)
Regulation of GABA release by dopamine in the rat substantia nigra. (1978) (5)
Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors (2014) (5)
Brunner's Gland Hyperplasia in a Patient after Roux-Y Gastric Bypass: An Important Pitfall in GLP-1 Receptor Imaging (2020) (5)
The effect of cochlear nerve lesion on the release of glutamate, aspartate, and GABA from cat cochlear nucleus, in vitro (2004) (4)
Combination therapy with [(Lys40(Ahx-[111In-DTPA])]-Exendin-4 and VEGF-receptor tyrosine kinase inhibitor PTK in a glucagon-like-peptide-1 receptor-positive transgenic mouse tumor model (2007) (4)
Effects of gonadotropin-releasing hormone and its agonists on prolactin secretion from normal and tumorous pituitary cells. (1989) (4)
Glucagon-like peptide-1 vs. somatostatin receptor targeting in malignant insulinoma (2010) (4)
In vitro release of 5-[3H]hydroxytryptamine from rat spinal trigeminal nucleus (1980) (4)
Preclinical evaluation of somatostatin analogs bearing two macrocyclic chelators for high specific activity labeling with radiometals (2007) (4)
Lack of evidence for cross-competition between vasoactive intestinal peptide and somatostatin at their respective receptors. (2001) (3)
A rare case of a large spinal meningioma with mediastinal extension and malignant behavior classified histologically as benign. (2013) (3)
Octreotide agent shows peptide imaging potential. (1993) (2)
Somatostatin and NPY (2006) (2)
Somatostatin Receptors in Gastroenteropancreatic Tumors (1996) (2)
GIP receptor: Expression in neuroendocrine tumours, internalization, signalling from endosomes and structure-function relationship studies (2019) (2)
‘Running on empty’ (2010) (2)
Approaches to improve the pharmacokinetics of radiolabeled GLP-1 receptor ligands using antagonistic tracers (2016) (2)
The Use of Sandostatin® in Insulinomas. The Relation Between In Vivo Responses, the Presence of Somatostatin Receptors and the Development of Tachyphylaxis (1989) (2)
Chapter 17 - Somatostatin (1997) (2)
Radiotherapeutic for Glucagon-Like Peptide-1Receptor ^ Targeted Therapy for Insulinoma (2007) (2)
111In-DTPA-exendin-4 SPECT/CT scans localize hardly detectable insulinomas (2009) (2)
Lys 40 ( Ahx-DTPA-111 In ) NH 2 ]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor ^ TargetedTherapy for (2007) (2)
PET/CT: A Pilot Study (2015) (2)
GPR 87 is an overexpressed G-protein coupled receptor in squamous cell carcinoma of the lung (2014) (2)
CHAPTER 154 – Somatostatin (2006) (2)
Glucagon-like peptide 1 receptor (GLP-1R) imaging for the preoperative localization of benign insulinomas in 30 patients (2012) (2)
EGF receptors in human breast cancer on viable and necrotic tumour cells (1988) (2)
Genetic changes in somatostatin receptor positive breast tumors (1990) (2)
The somatostatin analog Sandostatin (SMS201-995) in treatment of DMBA-induced rat mammary tumors (1990) (2)
[99mTc]Demomedin 1 for GRPR-targeted tumor imaging (2010) (2)
Novel PET/CT Imaging of Diffuse Parenchymal Lung Disease Combining a Labeled Somatostatin Receptor Analogue and F-18-FDG (2011) (2)
Use of Betidamino Acids in Drug Design (2006) (2)
Localisation of Insulinoma: Comparison of Glucagon-like Peptide-1 Receptor (GLP1-R) SPECT/CT, PET/CT and MRI. Preliminary results of a prospective clinical study. (2015) (1)
N-Methyl Scan of a sst1-Selective Somatostatin (SRIF) Analog (2001) (1)
First clinical evidence that radiolabeled somatostatin receptor antagonist may be preferable to agonists for the treatment of neuroendocrine tumors (2012) (1)
Pitfalls in the Detection of Insulinomas with GLP-1R Imaging (2020) (1)
Somatostatin receptors and cancer (1993) (1)
Erratum to “Analgesic activity of a non-peptide imidazolidinedione somatostatin agonist: In vitro and in vivo studies in rat” [Pain 124 (2006) 34–49] (2006) (1)
What is a false-positive somatostatin receptor scintigraphy? (1998) (1)
DOTAGA, a new chelator for Y-90 and In-111 based radiopeptides (2000) (1)
Somatostatin receptors in schwannomas. (1997) (1)
Guiding principles applied in the design of GPCR-selective hypothalamic hormone agonists and antagonists (2006) (1)
Expression of Somatostatin Receptors in Human Tissues in Health and Disease (2004) (1)
Absence of somatostatin receptors in psoriatic skin lesions (2004) (1)
Glucagon-like-1 Receptor imaging specifically localizes insulinomas in patients with Multiple Endocrine Neoplasia Type 1 (MEN-1) (2016) (1)
Makes the Difference (2011) (0)
Localization of benign Insulinomas using Glucagon-like Peptide-1 Receptor (GLP-1R) SPECT/CT and PET/CT in a prospective clinical study (2016) (0)
Receptors in Tumors of the Human Central Nervous System Distribution and Biochemical Characterization of Somatostatin (2006) (0)
Antagonists selective for somatostatin receptor (SSTR2) (2007) (0)
Localization of benign insulinomas using glucagon-like peptide-1 receptor (GLP1-R) SPECT/CT and PET/CT and MRI in a prospective clinical study (2016) (0)
New GRPR-antagonists mimicking [99mTc]Demobesin 1 (2014) (0)
Contents Vol. 94, 2011 (2011) (0)
Somatostatin analogues that bind to all somatostatin receptor subtypes, and to their use (2002) (0)
Persistent Lack of Somatostatin of Healing Ulcers in Rats (1994) (0)
Radionuclide Therapy : A Pilot Study Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor (2014) (0)
The receptors (SSTR2) -selective somatostatinantagonister (2007) (0)
Lu-DOTA-PESIN ) 177 Bi-AMBA versus 213 Bi-DOTA-PESIN and 213 Human Prostate Cancer Model ( Alpha-versus Beta-Particle Radiopeptide Therapy in a Updated (2011) (0)
Serum-stable neurotensin analogs as potential imaging and therapeutic agents for pancreatic cancer (2000) (0)
In Vitro Evaluation of Molecular Tumor Targets in Nuclear Medicine: Immunohistochemistry Is One Option, but Under Which Conditions? (2017) (0)
Supplementary Material for: A Critical Evaluation of sst3 and sst5 Immunohistochemistry in Human Pituitary Adenomas (2017) (0)
Development of 64Cu- and 68Ga-somatostatin receptor antagonists for improved PET imaging (2011) (0)
Are radiolabeled somatostatin receptor antagonists superior to agonists for in vivo tumor targeting (2007) (0)
Subject Index Vol. 11, 1994 (1994) (0)
Positive somatostatin receptorscintigraphy correlates withthepresenceofsomatostatin receptorsubtype 2 (1996) (0)
Primary extracranial grade 1 meningeoma extending through the intervertebral foramina C7-T4 with an extensive mediastinal mass (2011) (0)
Classified Histologically as Benign (2012) (0)
gastric and colonic smooth muscle cells Expression of somatostatin receptor subtypes on guinea pig (2011) (0)
Bombesin Receptor Subtypes in Human Cancers: Detection with the Universal Radioligand I-[ Bombesin(6 –14) (2002) (0)
Prevalence of somatostatin receptor subtype 2 in somatostatin receptor positive, gastroenteropancreatic neuroendocrine tumors (1995) (0)
Highly potent bombesin antagonist for PET and SPECT imaging of GRPr positive tumors: Effect of chelates on affinity and pharmacokinetics of radioligands (2009) (0)
Chapter 75 – Somatostatin/NPY (2013) (0)
Copper-64-labeled Sar-conjugated GRP receptor antagonists as new PET tracers for imaging of prostate cancer (2014) (0)
Subject Index, Vol. 54, Supplement 1, 1993 (1993) (0)
Biodistribution and targeted radiotherapy of [(Lys40(Ahx-[111In-DTPA])]-Exendin-4 in a Glucagon-like-Peptide-1 receptor-positive, tumor-bearing transgenic mouse model (2006) (0)
Comparison of SSTR2 agonist and antagonist peptides incorporating a novel 99mTc-chelator for targeting neuroendocrine tumors (2011) (0)
Synthesis and characterization of DOTA-coupled dimeric Y1 receptors antagonists for breast cancer targeting (2011) (0)
MINI-REVIEWS AND PERSPECTIVES Gastrin in Gastrointestinal Diseases (2011) (0)
Peptide Receptor Analysis in Neuroendocrine Gastroenteropancreatic Tumors (1994) (0)
Glucagon-like peptide-1 receptor SPECT/CT for the preoperative localization of benign insulinomas (2012) (0)
The Role of Somatostatin Receptor Scintigraphy in Gastroenteropancreatic Endocrine Tumors (1994) (0)
Toward 99mTc-based somatostatins with high affinity for all five somatostatin receptor subtypes (2008) (0)
[Central organization of transmitter systems]. (1979) (0)
and Substance P in Distinct Compartments of Human Lymphoid Organs Localization of Receptors for Vasoactive Intestinal Peptide, Somatostatin, (2009) (0)
Somatostatin receptors in apudomas: A physiological basis for therapy and a diagnostical tumour marker (1989) (0)
use on substance P based radiolabeled conjugates and their (2004) (0)
Unexpected sensitivity of SST2 antagonists to radiometal modifications (2012) (0)
Improved SSTR-2 binding affinities of yttrium- and gallium-labeled DOTA-octreotate and DOTAGA-octreotate (2000) (0)
Running title : Analog regulation of sst 2 signaling and endocytosis (2005) (0)
In vitro and in vivo characterization of a new somatostatin (SST) DOTA-conjugated analog (2009) (0)
Somatostatin analogues that all somatostatin receptors bind and use. (2002) (0)
Winner of the ESMI Young Investigator Award 2009 Dr . Abiraj Keelara Tetraamine-derived bifunctional chelators for 99 mTc labeling : synthesis , bioconjugation and evaluation as targeted SPECT imaging probes for GRPr positive tumors (2009) (0)
PL-5: DIAGNOSTIC AND THERAPEUTIC APPLICATION OF SOMATOSTATIN ANALOGS (1994) (0)
Solution structure of sst1-selective somatostatin (SRIF) analog (2005) (0)
A rare localization of a neuroendocrine tumor. (2011) (0)
Radiolabeled peptides for diagnosis and treatment of breast and prostate tumors as well as metastases of such tumors (1999) (0)
Towards antagonistic PET tracers for the GLP-1 receptor imaging with improved pharmacokinetics. (2015) (0)
Radiopeptide targeting for tumor therapy: peptide receptor distribution (2006) (0)
[Differentiation markers in breast carcinoma]. (1988) (0)
The potential role of technetium labeled bombesin analogs in the detection of bombesin-positive tumors in vivo (2000) (0)
Corrections to Highly Potent 4-Amino-indolo[2,3-c]azepin-3-one-Containing Somatostatin Mimetics with a Range of sst Receptor Selectivities (2010) (0)
Effects of lansoprazole and ranitidine on epithelial cell proliferation and cholecystokinin-B/gastrin receptors in the healthy human gastric stomach (2000) (0)
68Ga-exendin-4 PET/CT detects insulinomas in patients with hypoglycemia in multiple endocrine neoplasia type 1 (2019) (0)
Contents Vol. 80, 2004 (2005) (0)
Synthesis and peptide coupling of a new DOTA‐based prochelator, forming neutral complexes with yttrium‐90 and indium‐111 (2001) (0)
Tumors: In Vitro Identification (1996) (0)
Somatostatin and incretin receptor expression and trafficking in neuroendocrine tumors: Basic studies and their clinical implications (2012) (0)
Y1-Mediated Effect of Neuropeptide Y in Cancer (2001) (0)
Vasoactive Intestinal Peptide / Pituitary Adenylate Cyclase-activating Peptide Receptor Subtypes in Human Tumors and Their Tissues of Origin 1 (2000) (0)
Gastrin-releasing peptide receptors in the tumor vascular bed of various human cancers: high incidence in urinary tract cancers. (2009) (0)
Somatostatin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (0)
NMR strcutre of sst1-selective somatostatin (SRIF) analog 1 (2005) (0)
Subject Index Vol. 80, 2004 (2005) (0)
The Role of Somatostatin Receptors in the Diagnosis and Therapy of Cancer (1993) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jean‐claude Reubi?

Jean‐claude Reubi is affiliated with the following schools:

Jean‐claude Reubi's Academic­Influence.com Rankings

Why Is Jean‐claude Reubi Influential?

Jean‐claude Reubi's Published Works

Published Works

What Schools Are Affiliated With Jean‐claude Reubi?

Jean‐claude Reubi's AcademicInfluence.com Rankings